Neovascular age-related macular degeneration
Conditions
Brief summary
Proportion of patients without disease activity at week 8.
Detailed description
Proportion of patients with a 4, 6, 8, 10, 12, 14 or 16 week treatment interval between the 2nd aflibercept 8 mg loading dose and the 3rd aflibercept 8 mg injection, Change in best corrected visual acuity from baseline to week 4 and 8., Change in central subfield thickness and macular fluid volume from baseline to week 4 and 8., Characteristics/measurements in optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), angiography and best corrected visual acuity (BCVA) assessment, which can predict active/non-active disease.
Interventions
Sponsors
Medical University Of Graz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients without disease activity at week 8. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with a 4, 6, 8, 10, 12, 14 or 16 week treatment interval between the 2nd aflibercept 8 mg loading dose and the 3rd aflibercept 8 mg injection, Change in best corrected visual acuity from baseline to week 4 and 8., Change in central subfield thickness and macular fluid volume from baseline to week 4 and 8., Characteristics/measurements in optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), angiography and best corrected visual acuity (BCVA) assessment, which can predict active/non-active disease. | — |
Outcome results
None listed